AstraZeneca Partners Again with Daiichi Sankyo for its ADC Cancer Treatment

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 4 (Table of Contents)

Published: 3 Apr-2019

DOI: 10.3833/pdr.v2019.i4.2415     ISSN: 1756-7874

Section: Licensing



In their fifth collaboration together, AstraZeneca and Daiichi Sankyo have partnered up to develop and commercialise the latter’s lead antibody drug conjugate therapy, trastuzumab deruxtecan (DS-8201), for the treatment of breast and gastric cancers which are connected to the HER2 gene...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details